Skip to main content
. 2020 Sep 30;12:84. doi: 10.1186/s13098-020-00590-8

Table 2.

Blood tests and the three outcome variables according to gender

Overall
(N = 397)
Gender P
Men
(n = 178, 44.8%)
Women
(n = 219, 55.2%)
Blood tests
 FBG (in mg/dl) 96 (± 30.3) 102.70 (± 41.639) 91.53 (± 14.325) 0.000*
 2 h OGTT (in mg/dl) 111 (± 64.8) 125.74 (± 85.688) 99.70 (± 36.985) 0.000*
 TC (in mg/dl) 198 (± 41.2) 189.71 (± 42.258) 205.20 (± 39.196) 0.000*
 TG (in mg/dl) 139 (± 87.8) 160.97 (± 98.770) 122.65 (± 73.715) 0.000*
 HDL-C (in mg/dl) 48 (± 13.6) 41.56 (± 11.083) 54.04 (± 12.954) 0.000 *
 LDL-C (in mg/dl) 123 (± 36.9) 117.39 (± 39.656) 127.71 (± 33.955) 0.006*
 SBP (in mmHg) 121 (± 23.4) 125.48 (± 25.957) 117.65 (± 20.610) 0.001*
 DBP (in mmHg) 77 (± 15.3) 80.29 (± 17.013) 75.49 (± 13.547) 0.003*
 FINDRISC score 10 (± 4.2) 11.07 (± 4.685) 10.79 (± 3.958) 0.528
Outcomes
 UT2DM 30 (7.6%) 22 (12.4%) 8 (3.7%) 0.001*
 Prediabetes 91 (22.9%) 53 (29.8%) 38 (17.4%) 0.003*
 MS 142 (35.8%) 85 (47.7%) 57 (26%) 0.000*

*Statistical significance

FBG fasting blood glucose, 2h OGTT 2 hours oral glucose tolerance test, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood pressure, UTDM2 undiagnosed type 2 diabetes mellitus, MS metabolic syndrome